By Kelly Cloonan
Odyssey Therapeutics has withdrawn the initial public offering it filed for in January.
The Boston-based biopharmaceutical company on Monday asked the Securities and Exchange Commission to retract the filing, which did not disclose an expected share price or the number of shares it planned to sell.
Odyssey said it had determined that it was not in its best interests to of the company to conduct an offering at this time.
The company had planned to list shares on the Nasdaq under the ticker ODTX.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
June 09, 2025 17:16 ET (21:16 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.